Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NT 501

Drug Profile

NT 501

Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; Rexenus

Latest Information Update: 13 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurotech USA
  • Developer National Eye Institute; Neurotech USA; Stanford University; University of Miami
  • Class Cell therapies; Eye disorder therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal telangiectasis; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase III Retinal telangiectasis
  • Phase II/III Retinitis pigmentosa
  • Phase II Glaucoma; Usher syndromes
  • Phase I/II Colour vision defects
  • No development reported Dry macular degeneration; Optic nerve disorders

Most Recent Events

  • 12 Feb 2019 NT 501 receives Fast Track designation for Retinal telangiectasis [Intraocular,Implant] in USA
  • 20 Nov 2018 Neurotech Pharmaceuticals initiates enrolment in the phase III trial for Retinal telangiectasis in Australia, United Kingdom and USA (Intraocular) (EudraCT2017-003234-82) (NCT03316300)
  • 05 Oct 2018 Phase-III clinical trials in Retinal telangiectasis in France (Intraocular) (EudraCT2017-003234-82) (NCT03316300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top